Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 19

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 19
---
 we do not know when, or if at all, that will
occur. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical
activities and studies and initiate clinical trials. In addition, if we obtain regulatory approval for any programs, we expect to incur
significant expenses related to production of sales, marketing, and distribution to the extent that such sales, marketing and distribution
are not the responsibility of potential collaborators. We expect to incur additional costs associated with operating as a public company.

We
had net losses of $5.1 million and $1.4 million for the three months ended June 30, 2025 and 2024, respectively and, $7.2 million and
$7.7 million for the six months ended June 30, 2025 and 2024, respectively.

Highlights-Three
Months Ended June 30, 2025

●
On May 15, 2025, we announced the identification of Telomir-Ag2 as a novel drug candidate following successful preclinical validation
of its antimicrobial activity. Telomir-Ag2 is a stabilized Silver(II) complex developed using the Company’s proprietary Telomir-1
platform.

●
On May 29, 2025, we announced new preclinical data from its ongoing development of Telomir-1, an investigational oral small molecule
candidate being developed for the treatment of age-related macular degeneration.

●
On June 5, 2025, we announced new data from a preclinical study of its lead compound, Telomir-1, in a validated animal model of Werner
Syndrome (WS), an ultra-rare genetic disorder characterized by premature aging and shortened lifespan.

●
On June 11, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced new preclinical data demonstrating that its lead small molecule
candidate, Telomir-1, significantly improved neurological, behavioral, liver- and kidney-related outcomes in a clinically relevant animal
model of Wilson’s disease (ATP7B C271X -/- zebrafish).

●
On July 17, 2025, we reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft
model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by